肿瘤坏死因子相关凋亡诱导配体在心力衰竭中的研究进展  

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Heart Failure

作　　者：刘蕊 刘永铭[2] LIU Rui;LIU Yongming(The First Clinical Medical College of Lanzhou University,Lanzhou 730030,Gansu,China;Geriatric Cardiovascular Department,The First Hospital of Lanzhou University,Gansu Provincial Clinical Research Center for Geriatric Diseases,Lanzhou 730030,Gansu,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730030 [2]兰州大学第一医院老年心血管科/甘肃省老年疾病临床医学研究中心,甘肃兰州730030

出　　处：《心血管病学进展》2025年第4期322-326,共5页Advances in Cardiovascular Diseases

基　　金：甘肃省科技厅重点研发计划(20YF8FA079)。

摘　　要：心力衰竭作为全球性的重要卫生难题,因其复杂多样的发病机制,当下临床有效的治疗方法相对匮乏。肿瘤坏死因子相关凋亡诱导配体(TRAIL)属于肿瘤坏死因子超家族,因其可通过和受体结合,选择性地介导肿瘤细胞凋亡而在肿瘤治疗领域备受关注。近些年来,研究发现TRAIL不仅能发挥抗肿瘤作用,在心力衰竭相关的心肌细胞死亡和心室重塑的过程中也发挥着重要的作用。现综述TRAIL介导的信号通路及其在心力衰竭发生发展中的作用机制,探讨TRAIL及其受体在心力衰竭临床诊治中的潜在价值,以期为心力衰竭提供新的治疗途径。Heart failure,a global public health concern,has a complex and multifarious cause.At present,there are few clinical treatments available.The tumor necrosis factor superfamily’s tumor necrosis factor-related apoptosis-inducing ligand(TRAIL),has drawn extensive attention in tumor therapy for its ability to selectively induce apoptosis in tumor cells through receptor attachment.Recent studies have demonstrated that TRAIL not only exerts anti-tumor effects but also plays important biological roles in processes related to heart failure,including myocardial cell death and cardiac remodeling.This review delves into the signaling pathway mediated by TRAIL,the mechanisms of its action in the occurrence and development of heart failure,and explores the potential value of TRAIL and its receptors in the clinical diagnosis and treatment of heart failure,providing new treatments for heart failure patients.

关 键 词：心力衰竭 肿瘤坏死因子相关凋亡诱导配体 细胞凋亡 

分 类 号：R541.6[医药卫生—心血管疾病]